

Gisella Vischini, MD

Curriculum Vitae

Personal information

First name / Surname Gisella Vischini

Private Address Via Marcello Oretti 4 Bologna, Italy

Telephone Mobile: +39 328 0764814

E-mail vischini.gisella@gmail.com

Nationality Italy

Date of birth February 25th , 1979

Work experience

June 2020 to date

Nephrologist at Division of Nephrology and Dialysis and Transplantation Sant'Orsola University Hospital IRCCS, Bologna, Italy

2017-2018 Master in Renal Pathology, II level

2017 PhD degree in Nutrition & Metabolism

1-3-2016 \ 15-2-2017 Fellowship in Renal Pathology at Vanderbilt University, Nashville (TN)

2012 to 2020 Nephrologist at Division of Nephrology and Dialysis Columbus-Gemelli University Hospital

March-May 2012 Director of Nephrocare Dialysis Center in Cassino (Fr).

2010-2011 Nephrologist with a fixed term contract at Nephrology and Dialysis Unit of Civitanova Marche Hospital, Macerata

2009-2010 Medical collaboration with AIL (Italian Association for Lymphoma and Leukemia) foundation in Rome

2009-2010 Financial grant for scientific research (entitled: Valutazione in vitro della clearance di piperacillina tazobactam e dell'infusione continua tramite sacche di reinfusione in corso di CRRT come metodo ottimale per mantenere la concentrazione dell'antibiotico al di sopra della concentrazione minima inibente) supported by Fresenius Medical Care in Nephrology and Dialysis Unit of San Eugenio Hospital, Rome-Italy.

2009 Postgraduation in nephrology at Tor Vergata University of Rome (grade 50 cum laude)

2005-2007 Renal management of critical ill patients in several ICUs of private hospitals in Rome (plasmapheresis and renal replacement therapy)

1998 High School degree in Rome-Italy

Personal competences

Critical care nephrology
Peritoneal Dialysis
Renal Pathology

Mother tongue(s) Italian

Self-assessment
European level (*)

English

French

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
C1	C1	C1	C1	C1
A1	A1	A1	A1	A1

(*) [Common European Framework of Reference for Languages](#)

Social skills and competences

good ability to adapt to multicultural environments

Technical skills and competences

Renal histopathology
Management of renal patient

Computer skills and competences

good command of Microsoft Office™ tools (Word™, Excel™ and PowerPoint™) and iOS.

Publications

1. **Response to: 'Correspondence on 'Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications'' by Hakroush and Tampe. L'Imperio V, Vischini G, Ferraro M, Pagni F. Ann Rheum Dis. 2021 Feb 5: annrheumdis-2021-219988. doi: 10.1136/annrheumdis-2021-219988. Online ahead of print. PMID: 33547064 No abstract available.**
 2. **Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. Petricca L, Gigante MR, Paglionico A, Costanzi S, Vischini G, Di Mario C, Varriano V, Tanti G, Tolusso B, Alivernini S, Grandaliano G, Ferraccioli G, Gremese E. Front Med (Lausanne). 2020 Oct 28;7:553075. doi: 10.3389/fmed.2020.553075. eCollection 2020.PMID: 33195302**
 3. **Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated classifications. L'Imperio V, Vischini G, Pagni F, Ferraro PM. Ann Rheum Dis. 2020 Jun 12 doi: 10.1136/annrheumdis-2020-217979. Epub ahead of print. PMID: 32590212**
- SARS-CoV-2 in the peritoneal waste in a patient treated with peritoneal dialysis G,**

- D'Alonzo S, Grandaliano G, D'Ascenzo FM. *Kidney Int.* 2020 Jul;98(1):237-238. doi: 10.1016/j.kint.2020.05.005. Epub 2020 May 12.
5. **Proteinuria is a late-onset adverse event in patients treated with cabozantinib.** V, Moriconi D, Bonadio AG, Giannese D, La Manna G, Egidi MF, Comai G, Vischini G, Bottici V, Elisei R, Viola D. *J Endocrinol Invest.* 2020 May 3. doi: 10.1007/s40618-020-01272-y. Epub ahead of print.
 6. **Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report.** Calvaruso L, Naticchia A, Ferraro PM, Vischini G, Costanzi S. *Case Rep Nephrol.* 2019 Jul 9;2019:9264824. doi: 10.1155/2019/9264824. eCollection 2019.
 7. **Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury.** Masola V, Bellin G, Vischini G, Dall'Olmo L, Granata S, Gambaro G, Lupo A, Onisto M, Zaza G. *Oncotarget.* 2018 Nov 16;9(90)
 9. **MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy.** L'Imperio V, Smith A, Ajello E, Piga I, Stella M, Denti V, Tettamanti S, Sini co RA, Pieruzzi F, Garozzo M, Vischini G, Nebuloni M, Pagni F, Magni F. *Proteomics Clin Appl.* 2018 Oct 25:e1800019
 10. **A unique evolution of the kidney phenotype in a patient with autosomal recessive Alport syndrome.** Vischini G, Kapp ME, Wheeler FC, Hopp L, Fogo AB. *Hum Pathol.* 2018 Mar 9. pii: S0046-8177(18)30076-5. doi: 10.1016/j.humphath.2018.02.024. [Epub ahead of print]
 11. **Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein.** Milillo A, Molinaro C, Costanzi S, Vischini G, La Carpia F, La Greca F, Rigante D, Gambaro G, Gurrieri F, Sangiorgi E. *J Nephrol.* 2018 Mar 1. doi: 10.1007/s40620-018-0482-6.
 12. **Waldenstrom Macroglobulinemia.** Kapp M.E., Vischini G., Fogo A.B. # Springer International Publishing AG 2017 H. Trachtman et al. (eds.), *Glomerulonephritis*, DOI 10.1007/978-3-319-27334-1_37-1
 13. **Heparanase regulates the M1 polarization of renal macrophages and their crosstalk with renal epithelial tubular cells after ischemia/reperfusion injury.** Masola V, Zaza G, Bellin G, Dall'Olmo L, Granata S, Vischini G, Secchi MF, Lupo A, Gambaro G, Onisto M. *FASEB J.* 2018 Feb;32(2):742-756. doi: 10.1096/fj.201700597R
 14. **Heparanase: A Potential New Factor Involved in the Renal Epithelial Mesenchymal Transition (EMT) Induced by Ischemia/Reperfusion (I/R) Injury.** Masola V, Zaza G, Gambaro G, Onisto M, Bellin G, Vischini G, Khamaysi I, Hassan A, Hamoud S, Nativ O, Heyman SN, Lupo A, Vlodavsky I, Abassi Z. *PLoS One* 2016 Jul 28;11(7).
 15. **IgA nephropathy and infections.** Rollino C, Vischini G, Coppo R. *J Nephrol.* 2016 Aug;29(4):463-8.
 16. **A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy.** Milillo A, La Carpia F, Costanzi S, D'Urbano V, Martini M, Lanuti P, Vischini G, Larocca LM, Marchisio M, Miscia S, Amoroso A, Gurrieri F, Sangiorgi E. *Eur J Hum Genet* 2015 Dec;23(12):1673-8
 17. **[Membranous glomerulonephritis secondary to allogeneic stem cell transplant: review of the literature].** Vischini G, Niscola P, Ferrannini M, Cupelli L, Tendas A, Scaramucci L, Giovannini M, Dentamaro T, de Fabritiis P, Palumbo R. *G Ital Nefrol.* 2012;29(4):394-403
 18. **Pregnancy desire unmasks a MYH9 syndrome in a kidney transplant woman.** Vischini G, Farneti F, Niscola P, Stefoni A. *Saudi J Kidney Dis Transpl.* 2012 Jul;23(4):834-5.
 19. **Motor Disability in End-Stage Renal Failure: An Epidemiological Study on Italian Dialyzed Patients.** Vischini G, Tendas A, Ferrannini M, Scaramucci L, Di Segni G, Giovannini M, Niscola P, Palumbo R. *Saudi J Kidney Dis Transpl* 2011;22(6):1236-123.
 20. **Increased plasma levels of tacrolimus after ingestion of green tea.** Vischini G, Niscola P, Stefoni A, Farneti F. *Am J Kidney Dis.* 2011 Aug;58(2):329
 21. **Management of peritoneal dialysis within a home care program for haematological malignancies: concerns and perspectives illustrated by a case report.** Gisella Vischini, Pasquale Niscola, Andrea Tendas, Marco Giovannini, Luca Cupelli, Gregorio Antonio Brunetti, Michele Ferrannini, Claudio Cartoni, Paolo de Fabritiis, Roberto Palumbo. *Indian Journal of Palliative Care* . Volume 17 / Issue 2 / May-August 2011
 22. **Opioid analgesics in patients with chronic renal failure: principles for use and current guidelines.** Niscola P, Giovannini M, Vischini G, Scaramucci L, Ferrannini M, Tendas A, Cupelli L, Bondanini F, Di Daniele N, Palumbo R. *G Ital Nefrol.* 2011 May-Jun;28(3):269-77. Review. Italian.
 23. **Management of hematological malignancies in patients affected by renal failure.** Niscola P, Vischini G, Tendas A, Scaramucci L, Giovannini M, Bondanini F, Romani C, Brunetti GA,

- Cartoni C, Cupelli L, Ferrannini M, Perrotti A, Del Poeta G, Palumbo R, de Fabritiis P. *Expert Rev Anticancer Ther.* 2011 Mar;11(3):415-32. Review.
24. **Spontaneous bilateral kidney rupture during autologous stem cell transplantation in a patient affected by amyloidosis.** Ferrannini M, Vischini G, De Angelis G, Giannakakis K, Arcese W. *NDT Plus.* 2011 Feb;4(1):56-9. doi: 10.1093/ndtplus/sfq168. Epub 2010 Oct 5
 25. **Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol.** Strippoli GF; Clinical Evaluation of the DOse of Erythropoietins Study Group (C.E. DOSE). *Trials.* 2010 Jun 9;11:70.
 26. **Fulminant thrombotic microangiopathy as a clinical presentation of an occult signet-ring cell carcinoma of the lung and misdiagnosed as idiopathic thrombotic thrombocytopenic purpura.** Niscola P, Palmieri MB, Scaramucci L, Vischini G, Giovannini M, Ferrannini M, Palumbo R, Fratoni S. *Saudi Med J.* 2010 May;31(5):581
 27. **A very cheap renal replacement therapy in the intensive care unit: is it possible?** Ferrannini M, Vischini G, Palumbo R, Di Daniele N. *Artif Organs.* 2010 Jun;34(6):523; author reply 523-4. Epub 2010 Apr 20.
 28. **Pain management in multiple myeloma.** Niscola P, Scaramucci L, Romani C, Giovannini M, Tendas A, Brunetti G, Cartoni C, Palumbo R, Vischini G, Siniscalchi A, de Fabritiis P, Caravita T. *Expert Rev Anticancer Ther.* 2010 Mar;10(3):415-25.
 29. **The use of major analgesics in patients with renal dysfunction.** Niscola P, Scaramucci L, Vischini G, Giovannini M, Ferrannini M, Massa P, Tatangelo P, Galletti M, Palumbo R. *Curr Drug Targets.* 2010 Jun;11(6):752-8. Review.
 30. **Rituximab in post allogeneic hematopoietic stem cell transplantation membranous nephropathy: a case report.** Vischini G, Cudillo L, Ferrannini M, Di Daniele N, Cerretti R, Arcese W. *J Nephrol.* 2009 Jan-Feb;22(1):160-3.
 31. **Cystatin C: a promising misunderstood biomarker for the diagnosis of acute kidney injury.** Ferrannini M, Vischini G, Di Daniele N. *Kidney Int.* 2008 Dec;74(12):1623
 32. **Rituximab in membranous nephropathy after haematopoietic stem cell transplantation.** Ferrannini M, Vischini G, Di Daniele N. *Nephrol Dial Transplant.* 2008 Aug;23(8):2700-1;
 33. **Successful pregnancy in a uremic patient treated with single needle hemodialysis.** Ferrannini M, Vischini G, Miani N, Staffolani E, Di Daniele N. *Int J Artif Organs.* 2007 Dec;30(12):1122-5.
 34. **Rheopheresis in vascular diseases.** Ferrannini M, Vischini G, Staffolani E, Scaccia F, Miani N, Parravano MC, Louis MM, Splendiani G, Di Daniele N. *Int J Artif Organs.* 2007 Oct; 30(10):923-9

Bologna 07/26/2021